ReviewTranslational oncology2026
The PI3K/AKT signaling networks in cancer glucose metabolism: mechanisms and therapeutic implications.
Review in Translational oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The PI3K/AKT axis is frequently dysregulated and serves as a central regulator in cancer glucose metabolism. This review outlines the composition and activation mechanisms of the PI3K/AKT pathway, its interactions with core metabolic enzymes (hexokinase, pyruvate kinase, phosphofructokinase, aldolase, lactate dehydrogenase) and their non-canonical roles in cancer metabolism. We also dissect crosstalk between PI3K/AKT, the AMPK energy sensor, and major metabolic pathways (pentose phosphate pathway, oxidative phosphorylation, de novo lipogenesis). Further, we summarize latest advances in targeting metabolic enzymes and combined therapies, discuss challenges in targeting PI3K/AKT-mediated metabolic reprogramming, and propose future directions. Collectively, this review provides a theoretical framework for cancer metabolism mechanisms and identifies novel targets for cancer therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.